Equivalence of MammaPrint array types in clinical trials and diagnostics

Breast Cancer Research and Treatment

Volumn 156, Issue 2, 2016, Pages 279-287

  Beumer, Inès ^a   Witteveen, Anke ^a   Delahaye, Leonie ^a   Wehkamp, Diederik ^a   Snel, Mireille ^a   Dreezen, Christa ^a   Zheng, John ^a   Floore, Arno ^a   Brink, Guido ^a   Chan, Bob ^b   Linn, Sabine ^c   Bernards, Rene ^a   van ’T Veer, Laura ^a   Glas, Annuska ^a  

^a Agendia NV   (Netherlands)

^b Agendia Inc   (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Clinical prognostic value; Diagnostic microarray test; I SPY; MammaPrint; MINDACT

Indexed keywords

ACCURACY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMAPRINT ARRAY; MEASUREMENT REPEATABILITY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SURVIVAL; TISSUE PRESERVATION; BREAST TUMOR; DIAGNOSIS; EARLY CANCER DIAGNOSIS; GENE EXPRESSION PROFILING; GENETICS; PROCEDURES; SURVIVAL ANALYSIS; TISSUE MICROARRAY; TUMOR RECURRENCE;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TISSUE PRESERVATION;

EID: 84961801354     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-3764-5     Document Type: Article

References (36)

1. MammaPrint FDA clearance. See Decision Summary at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo. cfm?ID=DEN070009
2. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn H-J (2015) Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533-1546
3. NCCN Clinical Practice Guidelines in oncology for Breast Cancer version 3.2015. http://www.nccn.org/professionals/physi cian_gls/f_guidelines.asp
4. Glas AM, Floore A, Delahaye LJMJ, Witteveen AT, Pover RCF, Bakx N, Lahti-Domenici JST, Bruinsma TJ, Warmoes MO, Wessels LFA, Veer LJV (2006) Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7:278
5. Drukker CA, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van’t Tinteren H, Wesseling J, Roumen RMH, Knauer M, van Veer LJ, Sonke GS, Rutgers EJT, van de Vijver MJ, Linn SC (2013) A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 133:929-936
6. Sapino A, Roepman P, Linn SC, Snel MHJ, Delahaye LJMJ, van den Akker J, Glas AM, Simon IM, Barth N, de Snoo FA, van’t Veer LJ, Molinaro L, Berns EMJJ, Wesseling J, Riley LB, Anderson D, Nguyen B, Cox CE (2013) MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. J Mol Diagn 16:190-197
7. Drukker CA, Schmidt MK, Rutgers EJT, Cardoso F, Kerlikowske K, Esserman LJ, van Leeuwen FE, Pijnappel RM, Slaets L, Bogaerts J, Veer LJV (2014) Mammographic screening detects low-risk tumor biology breast cancers. Breast Cancer Res Treat 144:103-111
8. Krijgsman O, Roepman P, Zwart W, Carroll JS, Tian S, de Snoo FA, Bender RA, Bernards R, Glas AM (2011) A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat 133:37-47
9. van de Vijver MJ, He YD, Veer LJV, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH (2002) A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
10. Buyse M, Loi S, Veer LV, Viale G, Delorenzi M, Glas AM, d’Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ (2006) Validation and clinical utility of a 70-gene prognostic signature for women with nodenegative breast cancer. J Natl Cancer Inst 98:1183-1192
11. MammaPrint FDA clearance RNAretain. See Decision Summary at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn. cfm?ID=K070675
12. Bueno-de-Mesquita JM, van Harten WH, Veer LJV, van Dam FSAM, Karsenberg K, Douma KFL, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJT, Brink G, Floore AN, Glas AM, Roumen RMH, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC (2007) Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 8:1079-1087
13. MammaPrint FDA clearance FFPE. See Decision Summary at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn. cfm?ID=K141142
14. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167
15. FDA 510(k) Clearances. www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/ 510kClearances/default.htm
16. MammaPrint FDA clearance scanner. See Decision Summary at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn. cfm?ID=K080252
17. MammaPrint FDA clearance age 61 years. See Decision Summary at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/ pmn.cfm?ID=K081092
18. MammaPrint FDA clearance US location. See Decision Summary at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn. cfm?ID=K101454
19. Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Veer LJV (2008) The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116:295-302
20. Knauer M, Cardoso F, Wesseling J, Bedard PL, Linn SC, Rutgers EJT, van’t Veer LJ (2010) Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 103:1788-1793
21. Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJT, van’t Veer LJ (2009) The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 21:717-722
22. Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DSA, van Krimpen C, Meijers C, de Graaf PW, Bos MMEM, Hart AAM, Rutgers EJT, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, Veer LJV, van de Vijver MJ (2008) Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 117:483-495
23. Drukker CA, van Tinteren H, Schmidt MK, Rutgers EJT, Bernards R, van de Vijver MJ, Veer LJV (2014) Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res Treat 143:587-592
24. Cardoso F, Piccart-Gebhart M, Veer LV, Rutgers E (2007) The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol 1:246-251
25. Cardoso F, Veer LV, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26:729-735
26. Mook S, Veer LJV, Rutgers EJT, Piccart-Gebhart MJ, Cardoso F (2007) Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics 4:147-155
27. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ (2009) I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86:97-100
28. Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J (2005) Independence and reproducibility across microarray platforms. Nat Methods 2:337-344
29. Yauk CL, Berndt ML, Williams A, Douglas GR (2004) Comprehensive comparison of six microarray technologies. Nucleic Acids Res 32:e124
30. Fedorowicz G, Guerrero S, Wu TD, Modrusan Z (2009) Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas. BMC Med Genomics 2:23
31. Delahaye LJ, Wehkamp D, Floore AN, Bernards R, van’t Veer LJ, Glas AM (2013) Performance characteristics of the MammaPrint(R) breast cancer diagnostic gene signature. Personalized Med 10:801-811
32. Tholen DW, Kallner A, Kennedy JW, Krouwer JS, Meier K: Evaluation of precision performance of quantitative measurement methods. Approved Guideline. Second Edition. EP5-A2. National Committee on Clinical Laboratory Standards 2004, 24
33. Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu M-L, Borchik R, Mosquera J-M, Walker MG, Shak S (2005) Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 11:8623-8631
34. Ma X-J, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, Sotiriou C, Erlander M, Sgroi D (2008) A fivegene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14:2601-2608
35. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17:6012-6020
36. IVD regulation FDA. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm123682.htm